Understanding the long-term effect of alemtuzumab on the immune system of multiple sclerosis (MS) patients is crucial.
Objective:
To report a case of acute sarcoidosis (Löfgren’s syndrome) in a relapsing-remitting MS patient, 1.5 years after the second course of alemtuzumab treatment.
Case report:
Sarcoidosis was confirmed dermatohistologically, radiologically, and serologically. Analysis of the lymphocyte subpopulations showed a persistent effect of alemtuzumab treatment (CD4/CD8 ratio increased, absolute lymphocyte count of CD19-positive cells increased while CD3/4/8-positive cells were decreased).
Conclusion:
Our case highlights the profound effect of alemtuzumab on the immune system and its possible risk for autoimmune complications.
ColesAJCohenJAFoxEJet al. Alemtuzumab CARE-MS II 5-year follow-up. Neurology2017; 89(11): 1117–1126.
2.
HavrdovaEArnoldDLCohenJAet al. Alemtuzumab CARE-MS I 5-year follow-up: Durable efficacy in the absence of continuous MS therapy. Neurology2017; 89: 1107–1116.
3.
ZhangXTaoYChopraMet al. Differential reconstitution of T cell subsets following immunodepleting treatment with alemtuzumab (anti-CD52 monoclonal antibody) in patients with relapsing-remitting multiple sclerosis. J Immunol2013; 191: 5867–5874.
4.
MiedemaJRKaiserYBroosCEet al. Th17-lineage cells in pulmonary sarcoidosis and Löfgren’s syndrome: Friend or foe?J Autoimmun2018; 87: 82–96.
5.
Viana de AndradeACDBritoÉAHarrisOMOet al. Development of systemic sarcoidosis and xanthoma planum during multiple sclerosis treatment with interferon-beta 1a: Case report. Int J Dermatol2015; 54: e140–e145.
6.
TehARussellPLiJet al. Bone marrow sarcoidosis associated with long-term interferon-β treatment for multiple sclerosis. Clin Case Rep2016; 4: 1038–1040.
7.
RhoneEEChoPSPBirringSSet al. Pulmonary sarcoidosis in a patient with multiple sclerosis on daclizumab monotherapy. Mult Scler Relat Disord2017; 20: 25–27.
8.
ThachilJJadhavVGautamMet al. The development of sarcoidosis with the use of alemtuzumab—clues to T-cell immune reconstitution. Br J Haematol2007; 138: 559–560.
9.
O’ReganABermanJS.Sarcoidosis. Ann Intern Med2012; 156: ITC5-1–ITC5-16.
10.
HartungH-PAktasOBoykoAN.Alemtuzumab: A new therapy for active relapsing-remitting multiple sclerosis. Mult Scler2015; 21: 22–34.
11.
RezvanyMRTehraniMJKarlssonCet al. Reconstitution of the T-cell repertoire following treatment with alemtuzumab (anti-CD52 monoclonal antibody) in patients with B-cell chronic lymphocytic leukaemia. Br J Haematol2006; 135: 475–485.
12.
GrunewaldJEklundA.Role of CD4+ T cells in sarcoidosis. Proc Am Thorac Soc2007; 4: 461–464.
13.
BakerDHerrodSSAlvarez-GonzalezCet al. Interpreting lymphocyte reconstitution data from the pivotal phase 3 trials of alemtuzumab. JAMA Neurol2017; 74: 961–969.
